TYK Medicines’ Innovative Drug Project was Successfully Selected to 2022 Zhejiang Province Key Technology Innovation Program

TYK Medicines’ Innovative Drug Project was Successfully Selected to 2020 the Third Batch of Science and Technology Planning Projects

Livzon Pharmaceuticals and TYK Medicines Enter a Multi-targeted Kinase Inhibitor Greater China Equity Deal

TYK Medicines Received the Second Clinical Approval This Year with High Efficiency

An Open-label, Single-arm, and Multicenter Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Efficacy of TY-9591 Tablets for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

[recruitment] A Phase I Study to Evaluate the Safety, Tolerance, and Pharmacokinetics of TY-302 Capsule for the Treatment of Advanced Solid Tumors in China

TY-302 capsule is a CDK4/6 inhibitor